DEVELOPMENT AND SUPPLY AGREEMENT between LONZA SALES AG and MICROMET AGDevelopment and Supply Agreement • July 20th, 2010 • Micromet, Inc. • Biological products, (no disgnostic substances)
*** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Amendment No. 1Micromet, Inc. • July 20th, 2010 • Biological products, (no disgnostic substances)
Bayer and Micromet entered into an Option, Collaboration and License Agreement relating to BiTE antibodies on January 12, 2009 (hereinafter referred to as “the Agreement”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • July 20th, 2010 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is made and entered into effect as of October 28, 2009 (the “Effective Date”), by and between Micromet AG, having its principal place of business at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and sanofi-aventis, having its principal place of business at 174, avenue de France, 75635 Paris Cedex 13, France (“Sanofi”). Micromet and Sanofi each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
TERMINATION AND LICENSE AGREEMENTTermination and License Agreement • July 20th, 2010 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This Termination and License Agreement (the “Agreement”) is made and entered into effective as of November 4, 2009 (the “Effective Date”), by and between Micromet AG, having its principal place of business at Staffelseestrasse 2, 81477, Munich, Germany (“Micromet”), and MedImmune, LLC, having its principal place of business at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”). Micromet and MedImmune each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
